Buy & Sell Alnylam Pharmaceuticals, Inc. (ALNY) – Alnylam Pharmaceuticals, Inc. Price Today
Aura AI Summary
Key Stats
- $39.06BMarket Cap
- HealthSector
- -16.08%3M Drawdown
- $37.33BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 41 daysTypical Hold Time
Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $39.06B, with an enterprise value of $37.33B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $284.84 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -16.08%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 41 days, indicating typical investor behavior on the platform.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Most Recent News
Non-invasive blood glucose monitoring market to hit $340.49M by 2034 with 25.6% CAGR, driven by diabetes rise and tech advances
The global market for non-invasive blood glucose monitoring devices, which measure blood sugar without needles, is projected to grow from $34.86 million in 2024 to $340.49 million by 2034, at a CAGR of 25.6%. Growth is fueled by the increasing diabet...

IBM partners with Google Cloud to boost AI adoption and invests $10B in quantum computing by 2029
IBM has formed a strategic partnership with Google Cloud to accelerate AI adoption across industries like banking, retail, and telecom by launching a joint Google Cloud Practice. The collaboration aims to help customers deploy and manage AI at scale ...

REalloys secures exclusive rights to major Western heavy rare earth supply ahead of Pentagon's 2027 ban on Chinese materials.
REalloys has invested $20.6 million in the Saskatchewan Research Council's rare earth processing facility, gaining exclusive rights to up to 80% of its expanded heavy rare earth output, including critical metals like dysprosium and terbium. This move...
